Endocyte  
 

Our clinical development strategy is based on three fundamental principles. We believe that following these principles will lead to safer and more effective therapies.

  1. Use of companion imaging diagnostics to identify appropriate patients and indications.
  2. Improved potency of the therapy by using more highly active drugs and more frequent dosing.
  3. Lower toxicity through targeting so drug can be combined with other drugs.

Endocyte is currently sponsoring clinical trials related to several oncology product candidates. Click the links below for details on each study.

EC145: Folate-Receptor Targeted Chemotherapy

EC17: Folate-Receptor Targeted Hapten

EC0225: Folate-Receptor Targeted  Chemotherapy

  • Phase 1 solid tumor trial: enrollment complete.

EC0489: Folate-Receptor Targeted Chemotherapy

Medical professionals requiring additional information may contact clinical@endocyte.com.

Relevant Publications

 
Top
   

 

 

 
Purdue University National Ovarian Cancer Coalition